This NMA, the first to assess colorectal tumor risk across GLP-1 agonists and SGLT2 inhibitors, suggested that semaglutide, particularly the high-dose injectable formulation (2.4 mg/week) in individuals with obesity – may be associated with a dose–dependent increase in colorectal tumor incidence. The gene discussed is GCG; the disease is obesity disorder.